Trading Signals: BNTX Stock Price Prediction and Forecast (Thu. Oct. 10, 2019 - Fri. Jan. 15, 2021)(BioNTech SE )
| BNTX latest price $102.2200 (-3.23%) ($102.2200 - $102.2200) on Fri. Jan. 15, 2021. | |
| | Trend Analysis and Forecast | | | Trend Pattern | Uptrend Consolidation | Trend Narrative | Uptrend Reversal | Average Daily Price Swing | $8.48 (8.75% one month average) | Average Daily Percentage Swing | 5.61% (three month average) | Weekly Trend Force | 1.3% (StdDev 5.61%) | Daily Moving Force | -0.5% | Correction Force | Weak (0%) | Trend | 1.28% | Latest Price | $102.2200(-3.23%) | Forecasted Low Price | 100.79(-1.4%) | Forecasted High Price | 106.1(3.8%) | Direction of Next Movement | Range(2.4%) | % Change Needed to Confirm Correction | 1.3% (100.86) | % Change Needed for Trend Reversal | 6.5% | Hourly Trend | -0.2% [$103.93(-0.18), $104.02(-1.64)] | Complacency | 6 | Intraday Reversal Probability | N/A. | Daily Trend | BNTX advances 0.4% a day on average for past five trading days. | Weekly Trend | BNTX advances 10% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support BNTX decline at-0.5% a week (27% probability) CEMB(28%) EWP(27%) IVE(27%) XOP(27%) EWG(26%) | Factors Impacting BNTX price | BNTX will decline at least -0.6% in a week (22% probabilities). VIXM(-31%) BWX(-21%) VXX(-19%) GLD(-17%) SLV(-16%) | Explanation | The rally is not sustainable and not supported by the broad market. | Trading Plan | Buy the reversal | | | Valuation to SPY | 0.4 | | | Relative Volatility | -1.2 (options are cheap) | | | Market Trend Strength | 0.2% (StdDev 5.61%) | Hourly BBV | -1 () | Intraday Trend | 0% | | | |
|
Next Hour Price | $100.03(-2.14%) | Support Level | $96.89 | 5 Day Moving Average | $104.97(-2.62%) | 10 Day Moving Average | $98.6(3.67%) | 20 Day Moving Average | $96.89(5.5%) | To recent high | -20.5% | To recent low | 31.6% | Market Cap | $23.784b | | Option Sentiment | | | | Earning Release Date | Tue. Apr. 6, 2021 | Analyst One Year Target Price | $84.25 ($17.79 - $113.18) 9 analysts (last updated on Wed. Nov. 25, 2020) | % to Average Target Price | -17.58% | % to Low Target Price | -82.6% | % to High Target Price | 10.72% | | |
BioNTech SE operates as a clinical-stage biotechnology company. It operates through the following business units: Biotech Business and External Services. The Biotech Business unit consists of Clinical, Technology Platform and Manufacturing segments. It also includes business services operations. The External Services unit consists of External Services segment, which includes activities related to the sale of diagnostic products, peptides, retroviral vectors for clinical supply, development and manufacturing services. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
July 1, 2020. BioNTech and Pfizer have released the most detailed information so far among the vaccine candidates being tested in the U.S., 24 participants in the Phase 1/2 clinical trial who received two doses of the lower-dose vacc.ines developed neutralizing antibodies. |